Monoclonal antibody drugs are the fastest growing class
of biotherapeutics and have become a major part of the
biopharmaceutical market. Monoclonal antibodies have
demonstrated their effectiveness against autoimmune
disorders, cardiovascular diseases, infectious diseases, and
cancer.1
Monoclonal antibodies selectively recognize
antigens that are present on the tumor cells and exert
their cytotoxic effect by receptor agonist activity, immune
response, or vascular and stromal cell ablation.
United States
